Watch ZVRA. Know when insiders buy.
One email the day a filing lands. Free.
ZVRA
ZEVRA THERAPEUTICS, INC.
9.99
−0.19 −1.87%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
80
PASS · shorts 80
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $593.2MP/E 10.9DIV YIELD —FCF YIELD 5.50%REV TTM —NET INCOME $58.3M +2103.6%NET CASH $83.4M52W 8.10 – 14.75SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | $16.8M | $8.8M | −88.3% | 0.14 | $17M | $217K | $16.8M | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | $52.1M | $37.9M | — | 0.60 | $6.1M | $35K | $6.1M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | $9.3M | $12.2M | — | 0.19 | $5.5M | −$31K | $5.5M | Mar 9 |
| Q3 2025 · Sep 30 | — | — | — | $4.1M | −$544K | — | -0.01 | $4.7M | $554K | $4.2M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$71M | $74.7M | — | 1.21 | −$3.6M | $213K | −$3.8M | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$5.4M | −$3.1M | — | -0.06 | −$8.2M | $99K | −$8.3M | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$15.4M | −$35.7M | — | -0.69 | −$16.3M | $0 | −$16.3M | Mar 9 |
| Q3 2024 · Sep 30 | — | — | — | −$27.3M | −$33.2M | — | -0.69 | −$18.1M | $0 | −$18.1M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$23.8M | −$19.9M | — | -0.48 | −$19.1M | $0 | −$19.1M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$20.5M | −$16.6M | — | -0.40 | −$16.2M | $0 | −$16.2M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$15.2M | −$19.9M | — | -0.54 | −$16.2M | $72K | −$16.2M | Mar 12 |
| Q3 2023 · Sep 30 | — | — | — | −$15.4M | −$10.4M | — | -0.30 | −$4.6M | $172K | −$4.8M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$62.9M | $83.2M | — | 1.35 | −$1.6M | $835K | −$2.4M | — | — |
| FY2024 · to Dec 31 | — | — | −$87M | −$105.5M | — | -2.28 | −$69.7M | $0 | −$69.7M | $0 | — |
| FY2023 · to Dec 31 | — | — | −$49.6M | −$46M | — | -1.30 | −$33.5M | $296K | −$33.8M | $3.4M | — |
| FY2022 · to Dec 31 | — | — | −$42.6M | −$26.8M | — | -0.78 | −$18.7M | $93K | −$18.8M | $4.7M | — |
| FY2021 · to Dec 31 | — | — | $7.7M | −$8.6M | — | -2.11 | $10.4M | $102K | $10.3M | $2.8M | — |
| FY2020 · to Dec 31 | — | — | −$5.6M | −$12.8M | — | -3.21 | −$1.9M | $33K | −$2M | $0 | — |
Every number comes from ZEVRA THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.